跳至主要内容
临床试验/NCT02299843
NCT02299843Unknown不适用

A Prospective Randomized Controlled Trial of Radio-frequency Assisted ALPPS(RALPPS)and Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy(ALPPS)in the Treatment of Hepatocellular Carcinoma.

Southwest Hospital, China1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2014年10月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
发起方
入组人数
32
试验地点
1
主要终点
morbidity during perioperation

研究概览

简要总结

Currently,the "ALPPS" (associating liver partition with portal vein ligation for staged hepatectomy) procedure which enables the rapid growth of the future liver remnant and extends surgical indication to patients with mid-advanced stage hepatocellular carcinoma becomes a research hot spot. However, the procedure has a high morbidity and mortality rate.Using radio-frequency ablation instead of in-situ split of liver to avoid forming a coagulation band in stage I will reduce the incidence of complications(bile leakage, abdominal infection,hemorrhage e.t.) The investigators named this technique as Radio-frequency Assisted Liver Partition with Portal vein ligation for staged hepatectomy (RALPPS).Investigators hypothesized that the RALPPS might result in lower morbidity and mortality rate than ALPPS in the treatment of hepatocellular carcinoma . This Prospective Randomized Controlled Trial is on the Safety and Efficacy of radio-frequency assisted liver partition with portal vein ligation for staged hepatectomy for hepatocellular carcinoma.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • An insufficient future liver remnant(FLR<30% in normal hepatic function or FLR<40% with hepatic cirrhosis or after chemotherapy)
  • Liver function of Child-Pugh Class A or B.
  • Liver Reserve Function:ICG-R15≤10%
  • No evidence of coagulopathy: platelet count > 50 × 109/L and a prolonged prothrombin time of < 5 seconds.

排除标准

  • Patients met the inclusion criteria but declined to participate.
  • Patients with severe portal hypertension, a history of esophageal variceal hemorrhage, severe hypersplenism syndrome, or refractory ascites.
  • Main portal vein、inferior vena cava、common hepatic duct and hepatic vein have tumor thrombus.
  • Extrahepatic or lymph node metastasis

研究组 & 干预措施

ALPPS

Active Comparator

Using ALPPS for the the treatment of hepatocellular carcinoma.

干预措施: ALPPS (Procedure)

RALPPS

Experimental

Using radiofrequency ablation instead of in-situ split of liver in ALPPS stage I(RALPPS).Habib 4X was used in RFA.

干预措施: RALPPS (Procedure)

结局指标

主要结局

morbidity during perioperation

时间窗: 2 years

complications include bile leakage, abdominal infection, hemorrhage, PHLF e.t.

mortality during perioperation

时间窗: 2 years

次要结局

未报告次要终点

研究者

发起方
Southwest Hospital, China
申办方类型
Other
责任方
Principal Investigator
主要研究者

Yan Jun

institute of hepatobiliary surgery

Southwest Hospital, China

研究点 (1)

Loading locations...

相似试验

RALPPS Venus ALPPS for Hepatocellular Carcinoma | 临床试验